Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLIToneULTRA HDM Mix
- Development stage
- Phase 2
- Lead developer
- ALK Abelló
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Sublingual
01
Overview
SLIToneULTRA HDM Mix is a sublingual allergen immunotherapy (SLIT) product developed by ALK-Abelló A/S for the treatment of moderate-to-severe allergic rhinitis induced by house dust mites (HDM). It consists of standardized allergen extracts from the house dust mite species *Dermatophagoides pteronyssinus* (DP) and *Dermatophagoides farinae* (DF), formulated as sublingual drops. The therapy aims to modulate the immune system's response to HDM allergens by inducing IgE-blocking antibodies and promoting immunological tolerance. It was evaluated in the Phase 2 SUMMIT trial (NCT01728298), which demonstrated safety and tolerability across various dose levels (50, 150, and 300 SRU) in adult patients with moderate-to-severe HDM allergic rhinitis not controlled by symptomatic medication.
- Brand names
- SLIToneULTRA HDM Mix
- Other names
- SLIToneULTRA HDM mixSLIToneULTRAsublingual SLIToneULTRA house dust mite mix immunotherapy
02
Targets
House dust mite allergen proteins (Dermatophagoides pteronyssinus and Dermatophagoides farinae)IgE (Immunoglobulin E)
Beyond the preview
Go deeper on SLIToneULTRA HDM Mix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLIToneULTRA HDM Mix.